WO2003008637A3 - Use of genotyping in the individualization of therapy - Google Patents
Use of genotyping in the individualization of therapy Download PDFInfo
- Publication number
- WO2003008637A3 WO2003008637A3 PCT/CA2002/001103 CA0201103W WO03008637A3 WO 2003008637 A3 WO2003008637 A3 WO 2003008637A3 CA 0201103 W CA0201103 W CA 0201103W WO 03008637 A3 WO03008637 A3 WO 03008637A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- individualization
- therapy
- genotyping
- relates
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30563001P | 2001-07-17 | 2001-07-17 | |
US60/305,630 | 2001-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003008637A2 WO2003008637A2 (en) | 2003-01-30 |
WO2003008637A3 true WO2003008637A3 (en) | 2003-10-16 |
Family
ID=23181620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/001103 WO2003008637A2 (en) | 2001-07-17 | 2002-07-17 | Use of genotyping in the individualization of therapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003008637A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5348840B2 (en) | 2003-02-20 | 2013-11-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | How to choose a drug |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
WO2005038049A2 (en) * | 2003-10-06 | 2005-04-28 | Heinrich Guenther | System and method for optimizing drug therapy |
US8518022B2 (en) | 2004-08-27 | 2013-08-27 | Medimetrics Personalized Drug Delivery, Inc. | Electronically and remotely controlled pill and system for delivering at least one medicament |
JP2009517186A (en) * | 2005-11-29 | 2009-04-30 | チルドレンズ ホスピタル メディカル センター | Drug selection and medication optimization and personalization |
US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
CN101983029B (en) | 2008-03-31 | 2015-01-14 | 皇家飞利浦电子股份有限公司 | Method of preparing a swallowable capsule comprising a sensor |
WO2009153739A1 (en) | 2008-06-19 | 2009-12-23 | Koninklijke Philips Electronics N.V. | Device for delivery of powder like medication in a humid environment |
WO2009156919A1 (en) | 2008-06-25 | 2009-12-30 | Koninklijke Philips Electronics N.V. | Electronic pill comprising a plurality of medicine reservoirs |
EP2464414B1 (en) | 2009-08-12 | 2013-06-12 | Medimetrics Personalized Drug Delivery B.V. | Drug delivery device with compressible drug reservoir |
WO2014121133A2 (en) | 2013-02-03 | 2014-08-07 | Genelex Corporation | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
US20140274763A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to pain treatments |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055624A2 (en) * | 1999-03-15 | 2000-09-21 | Leyland Jones Brian | Elisa kit for the determination of metabolic phenotypes |
WO2002088753A1 (en) * | 2001-04-26 | 2002-11-07 | Mcgill University | Individualization of therapy with erectile dysfunction agents |
-
2002
- 2002-07-17 WO PCT/CA2002/001103 patent/WO2003008637A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055624A2 (en) * | 1999-03-15 | 2000-09-21 | Leyland Jones Brian | Elisa kit for the determination of metabolic phenotypes |
WO2002088753A1 (en) * | 2001-04-26 | 2002-11-07 | Mcgill University | Individualization of therapy with erectile dysfunction agents |
Non-Patent Citations (10)
Title |
---|
BROCKMÖLLER J ET AL: "Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.", PHARMACOGENOMICS. ENGLAND MAY 2000, vol. 1, no. 2, May 2000 (2000-05-01), pages 125 - 151, XP008020668, ISSN: 1462-2416 * |
ERESHEFSKY L ET AL: "REVIEW OF THE PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTION POTENTIAL OF ANTIDEPRESSANTS: FOCUS ON VENLAFAXINE", DEPRESSION AND ANXIETY, NEW YORK, NY, US, vol. 12, no. SUPPL 1, 2000, pages 30 - 44, XP009000372, ISSN: 1091-4269 * |
GRIESE E-U ET AL: "ASSESSMENT OF THE PREDICTIVE POWER OF GENOTYPES FOR THE IN-VIVO CATALYTIC FUNCTION OF CYP2D6 IN A GERMAN POPULATION", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 8, no. 1, February 1998 (1998-02-01), pages 15 - 26, XP001073429, ISSN: 0960-314X * |
INGELMAN-SUNDBERG M ET AL: "Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 8, 1 August 1999 (1999-08-01), pages 342 - 349, XP004173660, ISSN: 0165-6147 * |
LU A Y H: "Drug-metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 26, no. 12, December 1998 (1998-12-01), pages 1217 - 1222, XP002223866, ISSN: 0090-9556 * |
MANCINELLI L ET AL: "Pharmacogenomics: the promise of personalized medicine.", AAPS PHARMSCI [ELECTRONIC RESOURCE]. UNITED STATES 2000, vol. 2, no. 1, March 2000 (2000-03-01), pages E4, XP002251962, ISSN: 1522-1059 * |
MARCH R: "PHARMACOGENOMICS: THE GENOMICS OF DRUG RESPONSE", YEAST, CHICHESTER, SUSSEX, GB, vol. 17, no. 1, 2000, pages 16 - 21, XP001064496, ISSN: 0749-503X * |
MCELROY S ET AL: "CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.", AAPS PHARMSCI [ELECTRONIC RESOURCE]. UNITED STATES 2000, vol. 2, no. 4, 2000, pages E33, XP002251960, ISSN: 1522-1059 * |
MEISEL C ET AL: "HOW TO MANAGE INDIVIDUALIZED DRUG THERAPY: APPLICATION OF PHARMACOGENETIC KNOWLEDGE OF DRUG METABOLISM AND TRANSPORT", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, WALTER DE GRUYTER UND CO, DE, vol. 38, no. 9, September 2000 (2000-09-01), pages 869 - 876, XP001030015, ISSN: 1434-6621 * |
STREETMAN D S ET AL: "Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.", PHARMACOGENETICS. ENGLAND APR 2000, vol. 10, no. 3, April 2000 (2000-04-01), pages 187 - 216, XP008020500, ISSN: 0960-314X * |
Also Published As
Publication number | Publication date |
---|---|
WO2003008637A2 (en) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
HK1061679A1 (en) | Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use. | |
WO2004021968A3 (en) | Solution for ungual application | |
DE60115029D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES | |
ZA200405657B (en) | Formulation & dosage form for the controlled delivery of therapeutic agents. | |
IL157656A (en) | Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes | |
IL151400A0 (en) | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | |
WO2002069945A3 (en) | Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors | |
WO2005038049A3 (en) | System and method for optimizing drug therapy | |
ID30116A (en) | PIRIDOPIRANOAZEPIN DECREASES, THE PRODUCTION AND USE OF THERAPY | |
WO2003008637A3 (en) | Use of genotyping in the individualization of therapy | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
ID26612A (en) | SICLOBUTENA DECLARATIONS, THEIR PRODUCTION AND THE USE OF THERAPY | |
EP1257255A4 (en) | Therapeutic product, use and formulation thereof | |
EE200300363A (en) | Use of N- (Pyridinyl) -1H-Indole-1-Amine Compounds in the manufacture of a medicament for the treatment of diseases and conditions associated with myelin loss | |
WO2002053090A3 (en) | Medicinal association of a biguanine (metformin) and arginine | |
ZA200400313B (en) | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine. | |
AU2001243515A1 (en) | Combination drug therapy | |
TWI320413B (en) | 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof | |
WO2002053149A3 (en) | Medicament containing a polyamine as an active substance | |
HUP0204208A2 (en) | Antipruritic agents for external use | |
NO20042846L (en) | Derivatives of 5- (pyridin-3-yl) -1-azabicyclo [3.2.1] octane, preparation thereof and use of the same as therapeutic agents | |
AU2002244575A1 (en) | Individualization of therapy with antidepressants | |
AU2002349225A1 (en) | Individualization of therapy with antiviral agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002354840 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |